紫杉醇联合顺铂治疗晚期卵巢癌的临床疗效观察

目的探讨紫杉醇联合顺铂治疗晚期卵巢癌的临床疗效及不良反应。方法选取2008年10月～2010年6月我院收治的60例晚期卵巢癌病例,随机分为研究组和对照组,研究组采用紫杉醇联合顺铂化疗方案治疗,对照组采用顺铂、阿霉素联合环磷酰胺化疗方案治疗,30天为1个疗程,治疗均在2个疗程以上,观察其临床疗效及不良反应。结果经过2个疗程的治疗后,研究组治疗有效率为73.33%,其中10例腹水恢复正常;对照组有效率仅为40%,仅3例腹水恢复正常。研究组中位总生存期为38.5个月,1年生存率为76.67%,3年生存率为46.67%,5年生存率为36.67%。对照组中位总生存期为28.5个月,1年生存率为53.33%,3年生存率为33.33%,5年生存率为26.67%。研究组1、3、5年生存率均显著高于对照组(P<0.05)。研究组与对照组所出现的副反应相似,经过对症处理后均缓解或者痊愈。结论紫杉醇联合顺铂化疗方案治疗晚期卵巢癌疗效明显,不良反应可以接受,可作为晚期卵巢癌的化疗方案之一。

Observation on the Therapeutic Effects of Paclitaxel plus Cisplatin on Advanced Ovarian Carcinoma

Objective To explore the therapeutic effects of paclitaxel plus cisplatin on advanced ovarian carcinoma as well as its adverse reactions.Methods 60 cases of advanced ovarian carcinoma admitted to our hospital from October,2008 to June,2010 were selected and randomly divided into research group and control group.Patients in the research group were treated with paclitaxel plus cisplatin,while patients in the control group were treated with cisplatin,doxorubicin and cyclophosphamide.One treatment course lasted for 30 days,and all the patients were treated for more than two treatment courses.Then the therapeutic effects and adverse reactions were observed and evaluated.Results After two treatment courses,the effective rate of research group was 73.33%,10 cases of ascites subsidised,but the effective rate of control group was only 40%,just three cases of ascites subsidised.The median overall survival of study group was 38.5 months and 1-,3-,5-year survival rates were respectively 76.67%,46.67%,36.67%,while median overall survival of control group was 28 months,and 1-,3-,5-year survival rates were respectively 53.33%,33.33%,26.67%,which were all lower than that of research group(P<0.05).The incidences of adverse reactions in both groups were similar,which were all relieved or cured after symptomatic treatment.Conclusion Paclitaxel plus cisplatin had an obvious therapeutic effect on advanced ovarian cancer,and the adverse reactions were endurable,so it could be used as an alternative chemotherapy regimen for advanced ovarian cancer.